First update on the Brazilian consensus for the diagnosis and treatment of spondyloarthropathies: Ankylosing spondylitis and psoriatic arthritis;Consenso Brasileiro den espondiloartropatias: Espondilite anquilosante e artrite psoriásica diagnóstico e tratamento - Primeira revisão

Revista Brasileira de Reumatologia

Volumn 47, Issue 4, 2007, Pages 233-242

  Sampaio Barros, Percival D ^a,l   Azevedo, Valderílio Feijó ^b,m   Bonfiglioli, Rubens ^c   Campos, Wesley R ^d   Carneiro, Sueli Coelho da Silva ^e,n   Carvalho, Mario Antonio P ^d   Gonçalves, Célio Roberto ^f   Hilário, Maria Odete E ^g   Keiserman, Mauro W ^h   Leite, Nocy H ⁱ   Mallmann, Karen ^j   Meirelles, Eduardo de Souza ^f   Vieira, Walber P ^f,k   Ximenes, Antonio Carlos ^k  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c PONTIFÍCIA UNIVERSIDADE CATÓLICA DE CAMPINAS   (Brazil)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^e UNIVERSIDADE DO ESTADO DO RIO DE JANEIRO   (Brazil)

^f UNIVERSITY OF SÃO PAULO   (Brazil)

^g FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^h PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

ⁱ Faculdade Engenharia Souza Marques   (Brazil)

^j UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^k HOSPITAL GERAL DE FORTALEZA   (Brazil)

^l Hospital Geral de Fortaleza ^*  (Brazil)

^m Departamento de Medicina Interna

ⁿ FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; ATLIZUMAB; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; ETORICOXIB; HLA B27 ANTIGEN; INDOMETACIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PREDNISONE; SALAZOSULFAPYRIDINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; ARTICLE; BRAZIL; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; HUMAN; LIVER TOXICITY; PHYSIOTHERAPY; PSORIATIC ARTHRITIS; RECOMMENDED DRUG DOSE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SPONDYLOARTHROPATHY;

EID: 51449087847     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0482-50042007000400001     Document Type: Article

References (85)

1. Moll JHM, Haslock I, MacRae I, et al.: Associations between ankylosing spondylitis, psoriatic arthritis, Reiter's Psease, the intestinal arthropathies, and Behcet's syndrome. Medicine 53:343-64, 1974.
2. Braun J, Sieper J: Building consensus on nomenclature and disease classification for ankylosing spondylitis: results and discussion of a questionnaire prepared for the International Workshop on New Treatment Strategies in Ankylosing Spondylitis, Berlin, Germany, 18-19 January 2002. Ann Rheum Dis 61(Supl. III):61-7, 2002.
3. Dougados M, van der Linden S, Juhlin R, et al.: The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34:1218-27, 1991.
4. Van der Linden S, Van der Heijde D: Ankylosing spondylitis: clinical features. Rheum Dis Clin North Am 24:663-76, 1998.
5. Calin A, Elswood J, Rigg S, Skevington SM: Ankylosing spondylitis - An analytical review of 1,500 patients: the changing pattern of the disease. J Rheumatol 15:1234-8, 1988.
6. Reveille JD, Ball EJ, Khan MA: HLA-B27 and genetic predisposing factors in spondyloarthropathies. Curr Opin Rheumatol 13:265-72, 2001.
7. Sampaio-Barros PD, Bertolo MB, Kraemer MH, et al.: Primary ankylosing spondylitis: patterns of disease in a Brazilian population of 147 patients. J Rheumatol 28:560-5, 2001.
8. Wang SW, Davis JC Jr.: Clinical aspects of ankylosing spondylitis. In: Weisman MH, Reveille JD, van der Heijde D (eds). Ankylosing spondylitis and the spondyloarthropathies. Philadelphia: Mosby Elsevier, 2006;145-53.
9. Van der Linden S, Valkenburg HA, Cats A: Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 27:361-8, 1984.
10. Van der Heijde D, Landewe R: Assessment of disease activity, function, and quality of life. In: Weisman MH, Reveille JD, van der Heijde D (eds). Ankylosing spondylitis and the spondyloarthropathies. Philadelphia: Mosby Elsevier, 2006; 206-13.
11. Braun J, Baraliakos X: Imaging in ankylosing spondylitis. In: Weisman MH, Reveille JD, van der Heijde D (eds). Ankylosing spondylitis and the spondyloarthropathies. Philadelphia: Mosby Elsevier, 2006;187-204.
12. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286-91, 1994.
13. Cusmanich KG: Validação para a língua portuguesa dos instrumentos de avalição de índice funcional e índice de atividade de doença em pacientes com espondilite anquilosante. Dissertação de Mestrado em Ciências, Faculdade de Medicina da Universidade de São Paulo. Banco de Tese Capes, 2006.
14. Calin A, Garrett S, Whitelock H, et al.: A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281-5, 1994.
15. Shinjo SK, Goncalves R, Kowalski S, Goncalves CR: Brazilian-Portuguese version of the Health Assessment Questionnaire for Spondyloarthropathies (HAQ-S) in patients with ankylosing spondylitis: a translation, cross-cultural adaptation, and validation. Clin Rheumatol 2007; 26:1254-8.
16. Dagfιnrud H, Kvien TK, Hagen KB: The Cochrane review of physiotherapy interventions for ankylosing spondylitis. J Rheumatol 32: 1899-906, 2005.
17. Clegg DO: Treatment of ankylosing spondylitis. J Rheumatol 33(Supl. 78):24-31, 2006
18. Van der Heijde D, Baraf HS, Ramos-Remus C et al.: Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 52:1205-15, 2005.
19. Barkhuizen A Steinfeld S, Robbins J, West C, Coombs J, Zwillich S: Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. J Rheumatol 33:1805-12, 2006.
20. Wanders, Van der Heijde D, Landewé R, et al.: Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 52:1756-65, 2005.
21. Ward MM: Prospects for disease modification in ankylosing spondylitis: do nonsteroidal antiinflammatory drugs do more than treat symptoms? Arthritis Rheum 52:1634-6, 2005.
22. Dougados M, Dujkmans B, Khan M, Maksymowych W, Van der Linden S, Brandt J: Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 61 (Supl. III):40-50, 2002.
23. Peters ND, Ejstrup L: Intravenous methylprednisolone pulse therapy in ankylosing spondylitis. Scand J Rheumatol 21:134-8, 1992.
24. Braun J, Bollow M, Seyrekbasan F. et al.: Computed tomography guided corticosteroid injection of sacroliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol 23:659-64, 1996.
25. Gratacós J, Collado A, Pons F, et al.: Significant loss of bone mass in patients with early, active, ankylosing spondylitis: a followup study. Arthritis Rheum 42:2319-24, 1999.
26. Mitra D, Elvins DM, Speden DJ, Collins AJ: Prevalence of vertebral compression fractures in mild ankylosing spondylitis and their relationship to bone mineral density. Rheumatology 39-85-9, 2000.
27. Zochling J, Van der Heijde D, Burgos-Vargas R, et al.: ASAS/EULAR recommendations for the management of anklosing spondylitis. Ann Rheum Dis 65:442-52, 2006.
28. Dougados M, van der Linden S, Leirisalo-Repo M, et al.: Sulfasalazine in the treatment of spondylarthropathy: a randomized multicenter, double-blind, placebo-controlled study. Arthritis Rheum 38:618-27, 1995.
29. Benitez-del-Castilho JM, Garcia-Sanchez J, Iradier T, Bañares A: Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye 14:340-3, 2000.
30. Chen J, Liu C: Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 18(2): CD004800, 2005.
31. Sampaio-Barros PD, Costallat LTL, Bertolo MB, Marques Neto JF, Samara AM: Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 29:160-2, 2000.
32. Chen J, Liu C, Lin J: Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 18(4):CD004524, 2006.
33. Akkoc N, van der Linden S, Khan MA: Ankylosing spondylitis and symptom-modifying vs. disease modifying therapy. Best Pract Res Clin Rheumatol 20:539-57, 2006.
34. Huang F, Gu J, Zhao W, Zhu J, Zhang J, Yu DTY: One year open label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum 47:249-54, 2002.
35. Maksymowych WP, Jhangri GS, Fitzgerald A, et al.: A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal anti-inflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 46:766-73, 2002.
36. Van den Bosch F, Kruithof E, Baeten D, et al.: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 46:755-65, 2002.
37. Kruithof E, Van den Bosch F, Baeten D, et al.: Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 61:207-12, 2002.
38. Braun J, Landewe R, Hermann K-G, et al.: Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 54:1646-52, 2006.
39. Braun J, Brandt J, Listing J, et al.: Treatment of ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 359:1187-93, 2002.
40. Braun J, Brandt J, Listing J, et al.: Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Arthritis Rheum 48:2224-33, 2003.
41. Braun J, Baraliakos X, Listing J, Sieper J: Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52:2447-51, 2005.
42. Braun J, Baraliakos X, Brandt J, et al.: Persistent clinical response to the anti-TNF-α antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology 44:670-6, 2005.
43. Baraliakos X, Listing J, Brandt J, et al.: Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7:R439-44, 2005.
44. Baraliakos X, Listing J, Rudwaleit M, et al.: Safety and efficacy of readministration of infliximab after long-term continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol 34:510-5, 2007.
45. Brandt J, Khariouzov A, Listing J, et al.: Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48:1667-75, 2003.
46. Davis Jr. JC, van der Heijde D, Braun J, et al.: Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 48:3230-6, 2003.
47. Maksymowych WP, Poole AR, Hiebert L, et al.: Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol 32;1911-7, 2005.
48. Baraliakos X, Brandt J, Listing J, et al.: Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum 53:856-63, 2005.
49. Davis JC, Van der Heijde D, Braun J, et al.: Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 64;1557-62, 2005.
50. Van der Heijde D, Da Silva JC, Dougados M, et al.: Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 65:1572-7, 2006.
51. Van der Heijde D, Kivitz A, Schiff MH, et al.: Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Arthritis Rheum 54;2136-46, 2006.
52. Haibel H, Rudwaleit M, Brandt HC, et al.: Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 54:678-81, 2006.
53. Braun J, Davis J, Dougados M, et al.: First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 65:316-20, 2006.
54. Carmona L, Gomez-Reino JJ, on behalf of the BIOBADASER Group: Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther R72, 2006.
55. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J: Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis. Ann Rheum Dis 63:665-70, 2004.
56. Delaunay C, Farrenq V, Marini-Portugal A, et al.: Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheumatol 32:2183-5, 2005.
57. Moll JMH, Wright V: Psoriatic arthritis. Semin Arthritis Rheum 3:55-78, 1973.
58. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P: Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(Supl. II):ii14-ii17, 2005.
59. Griffiths CEM, Camp RDR, Barker JN: Psoriasis. In: Champion RH, Burton JL, Burns DA, et al. Rook/Wilkinson/Ebling Textbook of dermatology. 7a ed. Oxford: Blackwell Science, 2004;35.1-65.
60. Espinoza LR, Cuellar ML: Psoriatic arthritis and spondylitis: a clinical approach. In Calin A, Taurog JD (editors). Spondylarthritides. Oxford: Oxford University Press, 1998:97-111.
61. Mease P, Goffe BS: Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 52:1-19, 2005.
62. Balding J, Kane D, Livingstone W, et al.: Cytokine gene polymorphisms: Association with psoriatic arthritis susceptibility and severity. Arthritis Rheum 48:1408-13, 2003.
63. Sibilia J: Psoriasis: skin and joints, same fight? JEADV 20(Supl. 2):56-72, 2006.
64. Veale D, Ritchlin C, Fitz Gerald O: Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 65:26-9, 2005.
65. Taylor W, Gladman D, Helliwell P, et al.: Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665-73, 2006.
66. Khan M-F, Chamot A-M: SAPHO syndrome. Rheum Dis Clin North Am 18:225-46, 1992.
67. Kavanaugh AF, Ritchlin CT, and the GRAPPA Treatment Guideline Committee: Systematic review of treatment for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 33:1417-21, 2006.
68. Greaves MW, Weinstein GD: Treatment of psoriasis. New Engl J Med 332:581-8, 1995.
69. Gladman DD: Effectiveness of psoriatic arthritis therapies. Semin Arthritis Rheum 33:29-37, 2003.
70. Tsankov N, Kazandjieva J, Drenovska K: Drugs in exacerbation and provocation of psoriasis. Clin Dermatol 16:333-51, 1998.
71. Soriano ER, McHugH NJ: Therapies for peripheral joint disease in psoriatic arthritis: a systematic review. J Rheumatol 33:1422-30, 2006.
72. Espinoza LR, Zakraoui I, Espinoza CG, et al.: Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol 19:872-7, 1992.
73. Tilling L, Townsend S, David J: Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig 26:55-62, 2006.
74. Clegg DO, Reda RJ, Mejias E, et al.: Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum 39:2013-20, 1996.
75. Olivieri I, Salvarani C, Cantini F, et al.: Therapy with cyclosporine in psoriatic arthritis. Semin Arthritis Rheum 27:36-43, 1997.
76. Spadaro A, Riccieri V, Silli-Scavalli A, Sensis F, Taccari E, Zoppini A: Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 13:589-93, 1995.
77. Salvarani C, Macchioni P, Olivieri I, et al.: A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 28;2274-82, 2001.
78. Fraser AD, van Kujik AWR, Westhovens R, et al.: A randomised, double-blind, placebo-controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 64:859-64, 2005.
79. Kaltwasser JP, Nash P, Gladman D, et al.: Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50:1939-50, 2004.
80. Kavanaugh A, Krueger GG, Beutler A, et al.: Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 66:498-505, 2007.
81. Kavanaugh A, Antoni CE, Gladman D, et al.: The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 65:1038-43, 2006.
82. Mease PJ, Kivitz AJ, Burch FX, et al.: Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50:2264-72, 2004.
83. Mease PJ, Kivitz AJ, Burch FX, et al.: Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 33:712-21, 2006.
84. Gladman DD, Mease PJ, Ritchlin CT, et al.: Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 56:476-88, 2007.
85. Turkiewicz AM, Moreland LW: Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options. Arthritis Rheum 56:1051-66, 2007.